New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
The Pharma Data
DECEMBER 3, 2020
Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. The European Blood and Marrow Transplantation Textbook for Nurses: under the Auspices of EBMT. About Maribavir. Forward-Looking Statements.
Let's personalize your content